7-bromobenzo[d]oxazole-2-thiol | 1013643-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 7-bromobenzo[d]oxazole-2-thiol
• 英文别名: 7-bromo-3H-1,3-benzoxazole-2-thione
• CAS: 1013643-09-8
• 化学式: C₇H₄BrNOS
• 分子量: 230.085
• InChiKey: HQWNPEUAILIPCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-bromobenzo[d]oxazole-2-thiol 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 、 间氯过氧苯甲酸 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 三环己基膦 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 乙二醇二甲醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.25h， 生成 7-(5-fluoro-2-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)-1,3-benzoxazol-2-amine
  参考文献：
  名称：

  2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors

  摘要：

  2-Amino-7-substituted benzoxazole analogs were identified by HTS as inhibitors of RSK2. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus of improving in vitro and target modulation potency and physicochemical properties. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.058
• 作为产物：
  描述：

  2-溴-6-硝基苯酚 在 tin(II) chloride dihdyrate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 7-bromobenzo[d]oxazole-2-thiol
  参考文献：
  名称：

  N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

  摘要：

  本发明涉及式I的N-(杂)芳基吡咯烷衍生物： 这些是JAK抑制剂，如选择性JAK1抑制剂，在治疗JAK相关疾病方面具有用处，例如炎症和自身免疫性疾病，以及癌症。

  公开号：

  US20100298334A1

文献信息

• General Entry into <i>o</i> -,<i>o′</i> -Heteroatom-Linked <i>N</i> -(Hetero)aryl-Imidazole Motifs by Gold-Catalysed Formal [3+2]-Dipolar Cycloaddition
  作者：Miguel Garzón、Elsa M. Arce、Raju Jannapu Reddy、Paul W. Davies

  DOI：10.1002/adsc.201700249

  日期：2017.6.6

  general redox‐neutral approach into the o‐,o′‐heteroatom‐linked N‐(hetero)aryl‐imidazole family of heteroaromatics has been developed. New types of heteroatom substituted carbimidoyl nitrenoids are efficiently realised from robust, bench‐stable N‐(heteroaryl)‐pyridinium‐N‐aminides by formal gold‐catalysed [3+2]‐dipolar cycloadditions across ynamides. Broad structural variety and functional group tolerance

  已开发出一种将杂芳烃的邻，邻杂原子连接的N-（杂）芳基-咪唑家族的氧化还原中性方法。新型的杂原子取代的碳酰亚胺基亚硝基化合物可以通过稳定的，稳定的N-（杂芳基）-吡啶鎓-N-胺类化合物，通过正式的金催化的[3 + 2]-偶极环加成酰胺类有效地实现。广泛的结构多样性和官能团耐受性允许快速进入各种功能化的支架，如制备8个不同的杂芳族核心所示。
• Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20070093521A1

  公开（公告）日：2007-04-26

  This invention is concerned with compounds of the formula wherein X, A, B, R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物：其中X、A、B、R1、R2和G的定义如说明书和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这种化合物的制药组合物、它们的制备过程以及它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors
  申请人：Gerspacher Marc

  公开号：US20100009978A1

  公开（公告）日：2010-01-14

  The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.

  本发明涉及以下式I所示的2,7-二取代苯并噁唑和2,4-二取代噁唑并[5,4-c]吡啶化合物及其盐，以及其制备方法、在人或动物体内治疗过程中的应用，这些化合物用于动物（特别是人体）的治疗（包括预防），特别是与增殖性疾病有关的治疗，其使用 - 单独或与一个或多个其他药理活性化合物结合使用 - 用于治疗特别是蛋白酪氨酸激酶介导的疾病（如肿瘤疾病）或制造用于治疗此类疾病的制药制剂，以及用于治疗此类疾病的方法和制药制剂。这些化合物的式I如描述中所定义的符号。这些化合物可以抑制例如JAK2和JAK3。
• Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
  申请人：Gerspacher Marc

  公开号：US08629168B2

  公开（公告）日：2014-01-14

  The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.

  本发明涉及以下公式I所示的2,7-二取代苯并噁唑和2,4-二取代噁唑并[5,4-c]吡啶化合物及其盐，其制备方法，其在治疗人或动物体的过程中的应用，这些化合物用于治疗（包括预防）动物，特别是人体（特别是涉及增生性疾病的治疗），其用途 - 单独或与一种或多种其他药物活性化合物结合使用 - 用于治疗特别是蛋白酪氨酸激酶介导的疾病（例如肿瘤疾病）或用于制造用于治疗此类疾病的制药制剂，以及用于治疗所述疾病的方法和用于治疗所述疾病的制药制剂。这些化合物的公式I如描述中定义的符号所示。这些化合物抑制例如JAK2和JAK3。
• BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES
  申请人：Binggeli Alfred

  公开号：US20090163517A1

  公开（公告）日：2009-06-25

  This invention is concerned with compounds of the formula wherein X, A, B, R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及式中的化合物，其中X，A，B，R1，R2和G如说明书和权利要求所定义，并且其药学上可接受的盐。本发明还涉及含有这种化合物的制药组合物，以及用于治疗和/或预防与SST受体亚型5调节相关的疾病的方法。